Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02436759 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
A Phase 3 study of Acquired Blepharoptosis, sponsored by RVL Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 14
- Study locations
NCT02436759 is a Phase 3 study of Acquired Blepharoptosis that has completed, run by RVL Pharmaceuticals. The registered enrollment target is 140 participants. The trial reports 14 study locations across 7 states.
The verdict
NCT02436759, a Phase 3 study of Acquired Blepharoptosis, has completed, sponsored by RVL Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an extended dosing period of 6 weeks.
Conditions Studied
Interventions
- DRUG RVL-1201
- DRUG RVL-1201 Vehicle Placebo
Study Locations (14)
California
- - Artesia
- - Newport Beach
- - Rancho Cordova
- - Santa Maria
Florida
- - Fort Myers
- - Largo
- - Plantation
- - Sarasota
Kansas
- - Pittsburg
- - Shawnee Mission
Georgia
- - Roswell
Ohio
- - Mason
Pennsylvania
- - Kingston
Tennessee
- - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02436759
The ClinicalTrials.gov registry entry for NCT02436759 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RVL Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acquired Blepharoptosis appearing as the primary indexed condition, and to 2 interventions - of which RVL-1201 is the first listed.
NCT02436759 reports 14 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT02436759 about?
NCT02436759 is a clinical study titled "Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis". This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an extended dosing period of 6 weeks.
What is the current status of trial NCT02436759?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2015-05. Estimated completion is 2016-11.
What conditions does trial NCT02436759 study?
This clinical trial studies the following conditions: Acquired Blepharoptosis.
What interventions are being tested in trial NCT02436759?
The interventions under investigation include: RVL-1201 (DRUG), RVL-1201 Vehicle Placebo (DRUG).
Who is sponsoring clinical trial NCT02436759?
This trial is sponsored by RVL Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02436759 being conducted?
This trial has 14 study locations across California, Florida, Georgia, Kansas, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.